Official ESCRS | European Society of Cataract & Refractive Surgeons


A study comparing capsular changes following HOYA Vivinex® iSert and AcrySof IQ intraocular lens implantation in patients undergoing cataract surgery

Search Title by author or title

Session Details

Session Title: Cataract Surgery Complications

Session Date/Time: Monday 16/09/2019 | 16:30-18:00

Paper Time: 17:42

Venue: Free Paper Forum: Podium 2

First Author: : P.Sankhe INDIA

Co Author(s): :    S. Haldipurkar   V. Shetty   S. Tanwar   D. Shah   Z. Khatib   P. Nagvekar              

Abstract Details


To find out which IOL (Vivinex/Acrysof IQ) has comparatively less incidence of anterior and posterior capsular opacification .


Laxmi Eye Institute, tertiary eye care , Panvel, Navi Mumbai, Maharshtra, India.


A prospective study assessing 176 eyes implanted with Vivinex and Acrysof IQ IOL after an uneventful cataract surgery from January 2017 to October 2017. On follow up visits over 1, 3, 6 and 9 months for anterior capsular opacification: anterior capsular rim thickness nasally and temporally was assessed on Anterior Segment Optical Coherence Tomography, anterior capsular phimosis through slit lamp photograph by Adobe reader version 7.0 and lens opacity map on ITracey measured superiorly, inferiorly, temporally and nasally were studied whereas for posterior capsular opacification: EPCO (Evaluation of Posterior Capsular Opacification) 2000 software was used.


A larger anterior capsular rim thickness nasally (p<0.05) and temporally (p<0.05) was seen in Acrysof IQ compared to Vivinex and was statiscally significant on 3, 6 and 9 months. Anterior capsular phimosis was not appreciated in any of the lens. Lens opacity map showed more opacity with Acrysof IQ which was stastically significant in all the four quadrants(p<0.05) at 3, 6 and 9 months. EPCO score showed no statistically significant difference of posterior capsular opacification between the two IOLs at 9 months.


In direct comparison of Acrysof IQ and Vivinex IOLs, lower incidence of anterior capsular opacification is seen with Vivinex IOL at 3, 6 and 9 months. Both the IOLs had similar and low rate of posterior capsular opacification at 9 months.

Financial Disclosure:


Back to previous